Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12>>>
31 Items
Title  Creator  Group name  Publishing year 
The Translation of Dosimetry into Clinical Practice: What It Takes to Make Dosimetry a Mandatory Part of Clinical Practice Bardiès et al. EquipeJPP 2024-12-03
Symposium on molecular radiotherapy dosimetry: The first of a series? Bardiès et al. EquipeJPP 2024-04
Quality Assurance Considerations in Radiopharmaceutical Therapy Dosimetry Using PLANETDose: An International Atomic Energy Agency Study Kayal et al. EquipeJPP 2024-01-02
Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting Poty et al. EquipeJPP 2024-10-01
Implementation of dosimetry for molecular radiotherapy; results from a European survey Peters et al. EquipeJPP 2024-01
Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine Hebert et al. EquipeJPP 2024-06-03
Technical note: Impact of dose voxel kernel (DVK) values on dosimetry estimates in 177 Lu and 90 Y radiopharmaceutical therapy (RPT) applications Danieli et al. EquipeJPP 2023-09-15
Quality assurance in clinical dosimetry Bardiès EquipeJPP 2023
Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project Taprogge et al. EquipeJPP 2023-09
EFOMP policy statement NO. 19: Dosimetry in nuclear medicine therapy - Molecular radiotherapy Sjögreen-Gleisner et al. EquipeJPP 2023-12
Therapeutic efficacy of 166Holmium siloxane in microbrachytherapy of induced glioblastoma in minipig tumor model Khoshnevis et al. EquipeJPP 2022
Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals Korde et al. EquipeJPP 2022-07-19
Modelling SPECT auto-contouring acquisitions for 177Lu & 131I molecular radiotherapy using new developments in Geant4/GATE Kayal et al. EquipeJPP 2022-04
From the target cell theory to a more integrated view of radiobiology in Targeted radionuclide therapy: The Montpellier group's experience Pouget et al. EquipeJPP 2022
A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH) Deshayes et al. EquipeJPP 2022-12-22
Preclinical Pharmacokinetics and Dosimetry of an 89Zr Labelled Anti-PDL1 in an Orthotopic Lung Cancer Murine Model Krache et al. EquipeJPP 2021
Overview of commercial treatment planning systems for targeted radionuclide therapy Della Gala et al. EquipeJPP 2021-12-02
Generation of clinical 177Lu SPECT/CT images based on Monte Carlo simulation with GATE Kayal et al. EquipeJPP 2021-05
Advanced Monte Carlo simulations of emission tomography imaging systems with GATE Sarrut et al. EquipeJPP 2021-05-14
The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest Pichard et al. EquipeNB May 2020
Setting up a quantitative SPECT imaging network for a European multi-centre dosimetry study of radioiodine treatment for thyroid cancer as part of the MEDIRAD project Taprogge et al. EquipeJPP 2020-10-08
OpenDose: Open-Access Resource for Nuclear Medicine Dosimetry Chauvin et al. EquipeJPP 2020-10
Monte Carlo dosimetry of a realistic multicellular model of follicular lymphoma in a context of radioimmunotherapy Bordes et al. EquipeJPP 2020-10
Internal microdosimetry of alpha-emitting radionuclides Hofmann et al. EquipeJPP 2020-03
Feasibility of intratumoral 165Holmium siloxane delivery to induced U87 glioblastoma in a large animal model, the Yucatan minipig Khoshnevis et al. EquipeJPP 2020
12>>>
31 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés